These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 27770771

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group.
    J Am Coll Cardiol; 2009 Nov 17; 54(21):1971-81. PubMed ID: 19909879
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D, Beghetti M, Juaneda-Simian E, Ravindranath R, Lukas MA, Machlitt-Northen S, Scott N, Narita J, Berger RMF.
    Eur J Pediatr; 2024 May 17; 183(5):2141-2153. PubMed ID: 38366267
    [Abstract] [Full Text] [Related]

  • 6. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):529-35. PubMed ID: 16053970
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD.
    Respir Med; 2016 Aug 02; 117():254-63. PubMed ID: 27492539
    [Abstract] [Full Text] [Related]

  • 9. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z.
    Vasc Health Risk Manag; 2011 Aug 02; 7():119-24. PubMed ID: 21468170
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S, Shirato K, Shimamura R, Iwase T, Aoyagi N, Nakajima H.
    Curr Med Res Opin; 2012 Jun 02; 28(6):1069-76. PubMed ID: 22506623
    [Abstract] [Full Text] [Related]

  • 11. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
    He J, Wen L, Jiang R, Zhao QH, Wang L, Jiang X, Yan P, Bai L, Jing ZC.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun 02; 41(6):493-6. PubMed ID: 24113042
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension].
    Chen FD, Zhou DX, Di RM, Zou Y, Wei W, Liu XB.
    Zhonghua Yi Xue Za Zhi; 2013 Sep 10; 93(34):2736-8. PubMed ID: 24360110
    [Abstract] [Full Text] [Related]

  • 14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ, FREEDOM-C2 Study Team.
    Chest; 2013 Sep 10; 144(3):952-958. PubMed ID: 23669822
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S, Shirato K, Shimamura R, Nakahara N, Iwase T, Nakajima H.
    Curr Med Res Opin; 2011 Sep 10; 27(9):1827-34. PubMed ID: 21812736
    [Abstract] [Full Text] [Related]

  • 16. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
    Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ, ARIES-3 Study Group.
    Cardiovasc Ther; 2012 Apr 10; 30(2):93-9. PubMed ID: 21884013
    [Abstract] [Full Text] [Related]

  • 17. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, Anglen C, Kohan DE.
    Am J Cardiol; 2012 Nov 01; 110(9):1373-7. PubMed ID: 22858181
    [Abstract] [Full Text] [Related]

  • 18. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS.
    J Heart Lung Transplant; 2020 May 01; 39(5):464-472. PubMed ID: 32008947
    [Abstract] [Full Text] [Related]

  • 19. Ambrisentan.
    Croxtall JD, Keam SJ.
    Drugs; 2008 May 01; 68(15):2195-204. PubMed ID: 18840007
    [Abstract] [Full Text] [Related]

  • 20. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.